Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Transgene Identifier:
First received: June 23, 2011
Last updated: November 3, 2015
Last verified: November 2015